December 16, 2010 — Treatment with zoledronic acid (Zometa) appears to have benefits beyond bone health in patients with multiple myeloma. Researchers in the United Kingdom report that overall ...

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

December 12, 2008 (San Antonio, Texas) — New data suggest that zoledronic acid (Zometa, Novartis) has a direct effect on breast cancer. The bisphosphonate is currently marketed for osteoporosis and ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis prescribed zoledronic acid have an increased risk for atrial fibrillation when compared ...

Zoledronic acid administration during the initial hospitalization for osteoporotic hip fracture significantly reduces all-cause mortality and subsequent vertebral fractures among older patients.

A single intravenous dose of the osteoporosis drug zoledronic acid improved bone mineral density in a group of frail elderly women living in nursing homes and long-term-care facilities. A single ...

Preoperative Staging of Large Primary Breast Cancer With [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Compared With Conventional Imaging Procedures Adjuvant chemotherapy ...

RTOG 0518 evaluated the potential benefit of zoledronic acid therapy in preventing bone fractures for patients with high grade and/or locally advanced, non-metastatic prostate adenocarcinoma receiving ...

Novartis launches ready-to-use formulation of Zometa (zoledronic acid), a bone targeted agent for skeletal complications in advanced cancers and multiple myeloma Novartis launches ready-to-use ...